Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-11-21
2006-11-21
Parkin, Jeffrey S. (Department: 1648)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C435S343200, C424S188100
Reexamination Certificate
active
07138119
ABSTRACT:
This invention provides a composition which comprises an admixture of three compounds, wherein: (a) one compound is an antibody which binds to a CCR5 receptor; (b) one compound retards attachment of HIV-1 to a CD4+ cell by retarding binding of HIV-1 gp120 envelope glycoprotein to CD4 on the surface of the CD4+ cell; and (c) one compound retards gp41 from adopting a conformation capable of mediating fusion of HIV-1 to a CD4+ cell by binding noncovalently to an epitope on a gp41 fusion intermediate; wherein the relative mass ratio of any two of the compounds in the admixture ranges from about 100:1 to about 1:100, the composition being effective to inhibit HIV-1 infection of the CD4+ cell. This invention also provides a method of inhibiting HIV-1 infection of a CD4+ cell which comprises contacting the CD4+ cell with an amount of the composition of the subject invention effective to inhibit HIV-1 infection of the CD4+ cell so as to thereby inhibit HIV-1 infection of the CD4+ cell.
REFERENCES:
patent: 5225539 (1993-07-01), Winter
patent: 5464933 (1995-11-01), Bolognesi et al.
patent: 5603933 (1997-02-01), Dwyer et al.
patent: 5668149 (1997-09-01), Oroszlan et al.
patent: 5817767 (1998-10-01), Allaway et al.
patent: 5994515 (1999-11-01), Hoxie
patent: 6107019 (2000-08-01), Allaway et al.
patent: 6258782 (2001-07-01), Barney et al.
patent: 6344545 (2002-02-01), Allaway et al.
patent: 6528625 (2003-03-01), Wu et al.
patent: 6548636 (2003-04-01), Dragic et al.
patent: 6692745 (2004-02-01), Olson et al.
patent: 6759519 (2004-07-01), Li et al.
patent: 2002/0048786 (2002-04-01), Rosen et al.
patent: 2002/0061834 (2002-05-01), Rosen et al.
patent: 2002/0076745 (2002-06-01), Li et al.
patent: 2002/0099176 (2002-07-01), Li et al.
patent: 2002/0106742 (2002-08-01), Samson et al.
patent: 2002/0110805 (2002-08-01), Samson et al.
patent: 2002/0110870 (2002-08-01), Samson et al.
patent: 2002/0132269 (2002-09-01), Li et al.
patent: 2002/0146415 (2002-10-01), Olson et al.
patent: 2003/0023044 (2003-01-01), Li et al.
patent: 2003/0044411 (2003-03-01), Olson et al.
patent: 2003/0092632 (2003-05-01), Dragic et al.
patent: 2003/0228306 (2003-12-01), Olson et al.
patent: 9201451 (1992-02-01), None
patent: 9641020 (1996-12-01), None
patent: 9726009 (1997-07-01), None
patent: 9737005 (1997-10-01), None
patent: 9745543 (1997-12-01), None
patent: 9747319 (1997-12-01), None
patent: 9749424 (1997-12-01), None
patent: 9818826 (1998-05-01), None
patent: 9856421 (1998-12-01), None
patent: 0035409 (2000-06-01), None
patent: 0155439 (2001-08-01), None
patent: 0164710 (2001-09-01), None
patent: 0222077 (2002-03-01), None
patent: 02068608 (2002-09-01), None
patent: 02083172 (2002-10-01), None
patent: 03072766 (2003-09-01), None
Lee, B., et al., 1999, “Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function”, J. Biol. Chem. 274(14):9617-9626.
Furuta, R. A., et alk. 1998, “Capture of an early fusion-active conformation of HIV-1 gp41”, Nat. Strut. Biol. 5(4):276-279.
Valenzuela, A., et al., “Neutralizing antibodies against the V3 loop of human immunodeficiency virus type 1 gp120 block the CD4-dependent and -independent binding of virus to cells”, J. Virol. 71(11):8289-8298.
Olson, W. C., et al., “Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5”, J. Virol., May 1999, 73(5):4145-4155.
Trkola, A., “Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG”, J. Virol., Nov. 1995, 69(11):6609-6617.
Allaway, G.P. et al. (1995) Expression and characterization of CD4-IgG2, a novel heterotetramer which neutralizes primary HIV-1 isolates. AIDS Res. Hum. Retroviruses 11: 533-539.
Allaway, G.P. et al. (1993) Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41. AIDS Res. Hum. Retroviruses 9: 581-587.
Allaway, G.P. et al. (1993) Synergistic inhibition of HIV-1 envelope-mediated cell fusion by CD4-based molecules in combination with antibodies to gp120 or gp41. J. Cell. Biochem. 17E: 25, see abstract.
Amara, A. et al. (1997) HIV coreceptor downregulation as antiviral principle: SDF-la-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J. Exp. Med. 186: 139-146.
Arthos, J. et al. (1989) Identification of the residues in human CD4 critical for the binding of HIV. Cell 57: 469-481.
Berger, E.A. 1997. HIV entry and tropism: the chemokine receptor connection. AIDS 11 (suppl A): S3-S16.
Bieniasz, P.D. et al. (1997) HIV-1 induced cell fusion is mediated by multiple regions within both the viral envelope and the CCR5 co-receptor. EMBO J. 16:2599-2609.
U.S. Appl. No. 09/888,938, filed Jun. 25, 2001, Allaway et al.
Brelot, A. et al. (1997) Role of the first and third extracellular domains of CXCR4 in human immunodeficiency virus coreceptor activity. J. Virol. 71:4744-4751.
Burkly, L. et al. (1995) Synergistic inhibition of human immunodeficiency virus type 1 envelope glycoprotein-mediated cell fusion and infection by an antibody to CD4 domain 2 in combination with anti-gpl120 antibodies. J. Virol. 69:4267-4273.
Burton, D.R. et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024-1027.
Capon, D.J. et al. (1989) Designing CD4 immunoadhesins for AIDS therapy. Nature 337: 525-531.
Chan, D.C. et al. (1998) Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc. Natl. Acad. Sci. U.S.A. 95: 15613-15617.
Chan, D.C. et al. (1998) HIV entry and its inhibition. Cell 93: 681-684.
U.S. Appl. No. 10/323,314, filed Dec. 19, 2002, Dragic et al.
U.S. Appl. No. 08/627,684, filed Apr. 2, 1996. Allaway et al.
U.S. Appl. No. 60/014,532, filed Apr. 2, 1996, Allaway et al.
U.S. Appl. No. 08/663,616, filed Jun. 14, 1996, Allaway et al.
U.S. Appl. No. 60/019,715, filed Jun. 14, 1996, Allaway et al.
U.S. Appl. No. 08/673,682, filed Jun. 25, 1996, Allaway et al.
U.S. Appl. No. 08/665,090, filed Jun. 14, 1996, Allaway et al.
Chen, Z. et al. (1997) Genetically divergent strains of simian immunodeficiency virus-use CCR5 as a coreceptor for entry. J. Virol. 71: 2705-2714.
Choe, H. et al. (1996) The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85: 1135-1148.
Clapham, P.R. et al. (1989) Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells. Nature 337: 368-370.
Co, M.S. et al. (1991) Humanized antibodies for antiviral therapy. Proc. Natl. Acad. Sci. U.S.A. 88: 2869-2873.
Connor, R.I. et al. (1997) Change in co-receptor use correlates with disease progression in HIV-1 infected individuals. J. Exp. Med. 185: 621-628.
Crump, M.P. et al. (1997) Solution structure and basis for functional activity of stromal-cell derived factor-1; disassociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J. 16: 6996-7007.
U.S. Appl. No. 60/019,941, filed Jun. 14, 1996, Allaway et al.
U.S. Appl. No. 08/874,570, filed Jun. 13, 1997, Allaway et al.
U.S. Appl. No. 08/874,618, filed Jun. 13, 1997, Allaway et al.
U.S. Appl. No. 09/724,105, filed Nov. 28, 2000, Allaway et al.
U.S. Appl. No. 09/852,238, filed May 9, 2001, Allaway et al.
U.S. Appl. No. 09/212,793, filed Dec. 16, 1998, Olson et al.
U.S. Appl. No. 60/112,532, filed Dec. 16, 1998, Olson et al.
Cushman, M. et al. (1991) Preparation and anit-HIV activities of aurintricarboxylic acid fractions and analogues: direct correlation of antiviral potency with molecular weight. J. Med. Chem. 34: 329-337.
Dalgleish, A.G. et al. (1984) The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312: 763-766.
Deen, K.C. et al. (1988) A soluble form of CD4 (T4) protein inhibits AIDS virus in
Maddon Paul J.
Olson William C.
Cooper & Dunham LLP
Parkin Jeffrey S.
Progenics Pharmaceuticals Inc.
White, Esq. John P.
LandOfFree
Compositions and methods for inhibition of HIV-1 infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for inhibition of HIV-1 infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for inhibition of HIV-1 infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3628748